Cancer Immunotherapy - A Global Market Overview
Cancer Immunotherapy Market Trends and Outlook
Cancer immunotherapy, called immuno-oncotherapy, harnesses the body's immune system to identify and eliminate cancer cells. In contrast to traditional therapies like chemotherapy and radiation, which directly target cancer cells, immunotherapy enhances the immune response by utilizing tumor antigens that activate immune recognition. Monoclonal antibodies identify and tag cancer cells for elimination, while immune checkpoint inhibitors enhance the immune system's attack on tumors. Additionally, oncolytic viral therapies and cancer vaccines aim to destroy cancer cells or train the immune system to detect and attack cancer antigens more effectively. The effectiveness of these therapies varies across different cancer types, making them a significant focus in oncology research.
The global market for Cancer Immunotherapy is estimated at US$135.2 billion in 2024 and is anticipated to post a CAGR of 9.8% during the 2024-2030 analysis period and stand at a projected US$236.9 billion by 2030.
The global cancer immunotherapy market is primarily driven by the rising prevalence of cancer worldwide, leading to a growing demand for more effective treatment options. Oncolytic viral therapies and cancer vaccines use viruses to specifically target and destroy cancer cells, while Checkpoint inhibitors and CAR-T cell therapies are increasingly employed to treat lung cancer and melanoma. These therapies stimulate immune responses and are gaining attention due to their precise targeting and reduced side effects, further driving market demand. Advancements in biotechnology, including gene editing and bioinformatics, have enabled the development of personalized and efficient therapies. Additionally, investments in research and development and a supportive regulatory environment have accelerated the introduction of innovative treatments.
Cancer Immunotherapy Regional Market Analysis
North America dominates the market and is expected to hold an estimated share of 43.7% in 2024, primarily due to the increasing demand for advanced treatment options, a strong presence of major market players, and substantial investments in research and development. The United States leads this growth with favorable reimbursement policies and advanced healthcare infrastructure, which facilitates the adoption of immunotherapies. On the other hand, the Asia Pacific region is poised to be the fastest-growing market, with a projected CAGR of 11.3% during the forecast period 2024-2030. This growth is driven by a rising population of cancer patients, increased healthcare expenditures, and a growing awareness of innovative therapies in countries such as China and India. Government efforts to enhance healthcare infrastructure and a growing private sector are further driving this expansion, addressing the critical need for effective cancer treatments in both regions.
Cancer Immunotherapy Market Analysis by Product
The Monoclonal Antibodies segment dominates the cancer immunotherapy market, holding a projected share of 55.9% in 2024. This dominance is driven by growing R&D investments in bispecific, conjugated, and naked antigen-binding antibodies, which have created new growth opportunities in oncology therapeutics. These antibodies enhance adaptive immunity and specifically target cancer antigens, resulting in improved therapeutic outcomes with reduced side effects. In contrast, the Oncolytic Viral Therapies and Cancer Vaccines segment is expected to be the fastest-growing, with a projected CAGR of 11.8% during the analysis period 2024-2030, despite facing challenges like immunogenicity and immunosuppression in tumor environments.
Cancer Immunotherapy Market Analysis by Application
The lung cancer application is anticipated to maintain its dominant position by holding the largest market share of 13.8% in 2024. This growth is driven by the increasing prevalence of lung cancer, primarily due to increased smoking and the popularity of harmful products such as e-cigarettes. As the leading cause of cancer-related deaths globally, lung cancer requires immunotherapy treatments to manage the advanced stages of the disease. Meanwhile, the breast cancer application is expected to be the fastest-growing segment, with a projected CAGR of 13.5% during the forecast period 2024-2030, driven by the high prevalence of breast cancer, ongoing research and development efforts, and increased investments by leading players to develop novel therapeutics. The rising number of breast cancer cases among women globally further fuels this segment's expansion.
Cancer Immunotherapy Market Analysis by End-User
The Hospitals & Clinics segment is the largest end-user market, with an estimated share of 49.8% in 2024, primarily driven by the rising incidence of cancer, increased treatment rates, improved awareness, and the availability of immunotherapy treatments across numerous hospitals. The segment's significance is further strengthened by the growing number of hospital admissions for cancer treatment and the increased adoption of advanced therapies. Conversely, the Cancer Research Centers segment is anticipated to record the fastest growth with a CAGR of 10.9% during the analysis period from 2024 to 2030. This growth is driven by increasing investments in cancer research from corporate and government organizations, along with advancements in immunotherapy treatments.
Cancer Immunotherapy Market Report Scope
This global report on Cancer Immunotherapy analyzes the market based on product, application, and end-users. In addition to providing profiles of major companies operating in this space, the latest corporate and industrial developments have been covered to offer a clear panorama of how and where the market is progressing.
Key Metrics
Historical Period: 2021-2023
Base Year: 2023
Forecast Period: 2024-2030
Units: Value market in US$
Companies Mentioned: 10+
Cancer Immunotherapy Market by Geographic Region
Cancer immunotherapy, called immuno-oncotherapy, harnesses the body's immune system to identify and eliminate cancer cells. In contrast to traditional therapies like chemotherapy and radiation, which directly target cancer cells, immunotherapy enhances the immune response by utilizing tumor antigens that activate immune recognition. Monoclonal antibodies identify and tag cancer cells for elimination, while immune checkpoint inhibitors enhance the immune system's attack on tumors. Additionally, oncolytic viral therapies and cancer vaccines aim to destroy cancer cells or train the immune system to detect and attack cancer antigens more effectively. The effectiveness of these therapies varies across different cancer types, making them a significant focus in oncology research.
The global market for Cancer Immunotherapy is estimated at US$135.2 billion in 2024 and is anticipated to post a CAGR of 9.8% during the 2024-2030 analysis period and stand at a projected US$236.9 billion by 2030.
The global cancer immunotherapy market is primarily driven by the rising prevalence of cancer worldwide, leading to a growing demand for more effective treatment options. Oncolytic viral therapies and cancer vaccines use viruses to specifically target and destroy cancer cells, while Checkpoint inhibitors and CAR-T cell therapies are increasingly employed to treat lung cancer and melanoma. These therapies stimulate immune responses and are gaining attention due to their precise targeting and reduced side effects, further driving market demand. Advancements in biotechnology, including gene editing and bioinformatics, have enabled the development of personalized and efficient therapies. Additionally, investments in research and development and a supportive regulatory environment have accelerated the introduction of innovative treatments.
Cancer Immunotherapy Regional Market Analysis
North America dominates the market and is expected to hold an estimated share of 43.7% in 2024, primarily due to the increasing demand for advanced treatment options, a strong presence of major market players, and substantial investments in research and development. The United States leads this growth with favorable reimbursement policies and advanced healthcare infrastructure, which facilitates the adoption of immunotherapies. On the other hand, the Asia Pacific region is poised to be the fastest-growing market, with a projected CAGR of 11.3% during the forecast period 2024-2030. This growth is driven by a rising population of cancer patients, increased healthcare expenditures, and a growing awareness of innovative therapies in countries such as China and India. Government efforts to enhance healthcare infrastructure and a growing private sector are further driving this expansion, addressing the critical need for effective cancer treatments in both regions.
Cancer Immunotherapy Market Analysis by Product
The Monoclonal Antibodies segment dominates the cancer immunotherapy market, holding a projected share of 55.9% in 2024. This dominance is driven by growing R&D investments in bispecific, conjugated, and naked antigen-binding antibodies, which have created new growth opportunities in oncology therapeutics. These antibodies enhance adaptive immunity and specifically target cancer antigens, resulting in improved therapeutic outcomes with reduced side effects. In contrast, the Oncolytic Viral Therapies and Cancer Vaccines segment is expected to be the fastest-growing, with a projected CAGR of 11.8% during the analysis period 2024-2030, despite facing challenges like immunogenicity and immunosuppression in tumor environments.
Cancer Immunotherapy Market Analysis by Application
The lung cancer application is anticipated to maintain its dominant position by holding the largest market share of 13.8% in 2024. This growth is driven by the increasing prevalence of lung cancer, primarily due to increased smoking and the popularity of harmful products such as e-cigarettes. As the leading cause of cancer-related deaths globally, lung cancer requires immunotherapy treatments to manage the advanced stages of the disease. Meanwhile, the breast cancer application is expected to be the fastest-growing segment, with a projected CAGR of 13.5% during the forecast period 2024-2030, driven by the high prevalence of breast cancer, ongoing research and development efforts, and increased investments by leading players to develop novel therapeutics. The rising number of breast cancer cases among women globally further fuels this segment's expansion.
Cancer Immunotherapy Market Analysis by End-User
The Hospitals & Clinics segment is the largest end-user market, with an estimated share of 49.8% in 2024, primarily driven by the rising incidence of cancer, increased treatment rates, improved awareness, and the availability of immunotherapy treatments across numerous hospitals. The segment's significance is further strengthened by the growing number of hospital admissions for cancer treatment and the increased adoption of advanced therapies. Conversely, the Cancer Research Centers segment is anticipated to record the fastest growth with a CAGR of 10.9% during the analysis period from 2024 to 2030. This growth is driven by increasing investments in cancer research from corporate and government organizations, along with advancements in immunotherapy treatments.
Cancer Immunotherapy Market Report Scope
This global report on Cancer Immunotherapy analyzes the market based on product, application, and end-users. In addition to providing profiles of major companies operating in this space, the latest corporate and industrial developments have been covered to offer a clear panorama of how and where the market is progressing.
Key Metrics
Historical Period: 2021-2023
Base Year: 2023
Forecast Period: 2024-2030
Units: Value market in US$
Companies Mentioned: 10+
Cancer Immunotherapy Market by Geographic Region
- North America (The United States, Canada, and Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, and Rest of Europe)
- Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)
- South America (Brazil, Argentina, and Rest of South America)
- Rest of World
- Monoclonal Antibodies
- Oncolytic Viral Therapies & Cancer Vaccines
- Checkpoint Inhibitors & Immunomodulators
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Skin Cancer
- Prostate Cancer
- Stomach Cancer
- Head & Neck Cancer
- Others (Including Blood, Ovarian, Cervical, Kidney, Liver, Bladder, Pancreatic, and other cancers)
- Hospitals & Clinics
- Cancer Research Centers
- Other End-Users (Including Ambulatory Surgical Centers (ASCs), and Homecare settings)
PART A: GLOBAL MARKET PERSPECTIVE
1. INTRODUCTION
Product Outline
Cancer Immunotherapy Defined
Cancer Immunotherapy Products
Monoclonal Antibodies
Oncolytic Viral Therapies & Cancer Vaccines
Checkpoint Inhibitors & Immunomodulators
Cancer Immunotherapy Applications
Lung Cancer
Breast Cancer
Colorectal Cancer
Skin Cancer
Prostate Cancer
Stomach Cancer
Head & Neck Cancer
Others (Including Blood, Ovarian, Cervical, Kidney, Liver, Bladder, Pancreatic, and other cancers)
Cancer Immunotherapy End-Users
Hospitals & Clinics
Cancer Research Centers
Other End-Users (Including Ambulatory Surgical Centers (ASCs), and Homecare settings)
2. Key Market Trends
3. Key Global Players
Amgen Inc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche AG
GSK Plc
Immunocore Holdings Plc
Johnson & Johnson Innovative Medicine
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
4. Key Business & Product Trends
5. Global Market Overview
Global Cancer Immunotherapy Market Overview by Product
Cancer Immunotherapy Product Market Overview by Global Region
Monoclonal Antibodies
Oncolytic Viral Therapies & Cancer Vaccines
Checkpoint Inhibitors & Immunomodulators
Global Cancer Immunotherapy Market Overview by Application
Cancer Immunotherapy Application Market Overview by Global Region
Lung Cancer
Breast Cancer
Colorectal Cancer
Skin Cancer
Prostate Cancer
Stomach Cancer
Head & Neck Cancer
Others
Global Cancer Immunotherapy Market Overview by End-User
Cancer Immunotherapy End-User Market Overview by Global Region
Hospitals & Clinics
Cancer Research Centers
Other End-Users
PART B: REGIONAL MARKET PERSPECTIVE
Global Cancer Immunotherapy Market Overview by Geographic Region
REGIONAL MARKET OVERVIEW
6. North America
North American Cancer Immunotherapy Market Overview by Geographic Region
North American Cancer Immunotherapy Market Overview by Product
North American Cancer Immunotherapy Market Overview by Application
North American Cancer Immunotherapy Market Overview by End-User
Country-wise Analysis of North American Cancer Immunotherapy Market
The United States
United States Cancer Immunotherapy Market Overview by Product
United States Cancer Immunotherapy Market Overview by Application
United States Cancer Immunotherapy Market Overview by End-User
Canada
Canadian Cancer Immunotherapy Market Overview by Product
Canadian Cancer Immunotherapy Market Overview by Application
Canadian Cancer Immunotherapy Market Overview by End-User
Mexico
Mexican Cancer Immunotherapy Market Overview by Product
Mexican Cancer Immunotherapy Market Overview by Application
Mexican Cancer Immunotherapy Market Overview by End-User
7. Europe
European Cancer Immunotherapy Market Overview by Geographic Region
European Cancer Immunotherapy Market Overview by Product
European Cancer Immunotherapy Market Overview by Application
European Cancer Immunotherapy Market Overview by End-User
Country-wise Analysis of European Cancer Immunotherapy Market
Germany
German Cancer Immunotherapy Market Overview by Product
German Cancer Immunotherapy Market Overview by Application
German Cancer Immunotherapy Market Overview by End-User
France
French Cancer Immunotherapy Market Overview by Product
French Cancer Immunotherapy Market Overview by Application
French Cancer Immunotherapy Market Overview by End-User
The United Kingdom
United Kingdom Cancer Immunotherapy Market Overview by Product
United Kingdom Cancer Immunotherapy Market Overview by Application
United Kingdom Cancer Immunotherapy Market Overview by End-User
Italy
Italian Cancer Immunotherapy Market Overview by Product
Italian Cancer Immunotherapy Market Overview by Application
Italian Cancer Immunotherapy Market Overview by End-User
Spain
Spanish Cancer Immunotherapy Market Overview by Product
Spanish Cancer Immunotherapy Market Overview by Application
Spanish Cancer Immunotherapy Market Overview by End-User
Rest of Europe
Rest of Europe Cancer Immunotherapy Market Overview by Product
Rest of Europe Cancer Immunotherapy Market Overview by Application
Rest of Europe Cancer Immunotherapy Market Overview by End-User
8. Asia-Pacific
Asia-Pacific Cancer Immunotherapy Market Overview by Geographic Region
Asia-Pacific Cancer Immunotherapy Market Overview by Product
Asia-Pacific Cancer Immunotherapy Market Overview by Application
Asia-Pacific Cancer Immunotherapy Market Overview by End-User
Country-wise Analysis of Asia-Pacific Cancer Immunotherapy Market
Japan
Japanese Cancer Immunotherapy Market Overview by Product
Japanese Cancer Immunotherapy Market Overview by Application
Japanese Cancer Immunotherapy Market Overview by End-User
China
Chinese Cancer Immunotherapy Market Overview by Product
Chinese Cancer Immunotherapy Market Overview by Application
Chinese Cancer Immunotherapy Market Overview by End-User
India
Indian Cancer Immunotherapy Market Overview by Product
Indian Cancer Immunotherapy Market Overview by Application
Indian Cancer Immunotherapy Market Overview by End-User
South Korea
South Korean Cancer Immunotherapy Market Overview by Product
South Korean Cancer Immunotherapy Market Overview by Application
South Korean Cancer Immunotherapy Market Overview by End-User
Rest of Asia-Pacific
Rest of Asia-Pacific Cancer Immunotherapy Market Overview by Product
Rest of Asia-Pacific Cancer Immunotherapy Market Overview by Application
Rest of Asia-Pacific Cancer Immunotherapy Market Overview by End-User
9. South America
South American Cancer Immunotherapy Market Overview by Geographic Region
South American Cancer Immunotherapy Market Overview by Product
South American Cancer Immunotherapy Market Overview by Application
South American Cancer Immunotherapy Market Overview by End-User
Country-wise Analysis of Asia-Pacific Cancer Immunotherapy Market
Brazil
Brazilian Cancer Immunotherapy Market Overview by Product
Brazilian Cancer Immunotherapy Market Overview by Application
Brazilian Cancer Immunotherapy Market Overview by End-User
Argentina
Argentine Cancer Immunotherapy Market Overview by Product
Argentine Cancer Immunotherapy Market Overview by Application
Argentine Cancer Immunotherapy Market Overview by End-User
Rest of South America
Rest of South American Cancer Immunotherapy Market Overview by Product
Rest of South American Cancer Immunotherapy Market Overview by Application
Rest of South American Cancer Immunotherapy Market Overview by End-User
10. Rest of World
Rest of World Cancer Immunotherapy Market Overview by Product
Rest of World Cancer Immunotherapy Market Overview by Application
Rest of World Cancer Immunotherapy Market Overview by End-User
PART C: GUIDE TO THE INDUSTRY
PART D: ANNEXURE
1. RESEARCH METHODOLOGY
2. FEEDBACK
1. INTRODUCTION
Product Outline
Cancer Immunotherapy Defined
Cancer Immunotherapy Products
Monoclonal Antibodies
Oncolytic Viral Therapies & Cancer Vaccines
Checkpoint Inhibitors & Immunomodulators
Cancer Immunotherapy Applications
Lung Cancer
Breast Cancer
Colorectal Cancer
Skin Cancer
Prostate Cancer
Stomach Cancer
Head & Neck Cancer
Others (Including Blood, Ovarian, Cervical, Kidney, Liver, Bladder, Pancreatic, and other cancers)
Cancer Immunotherapy End-Users
Hospitals & Clinics
Cancer Research Centers
Other End-Users (Including Ambulatory Surgical Centers (ASCs), and Homecare settings)
2. Key Market Trends
3. Key Global Players
Amgen Inc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche AG
GSK Plc
Immunocore Holdings Plc
Johnson & Johnson Innovative Medicine
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
4. Key Business & Product Trends
5. Global Market Overview
Global Cancer Immunotherapy Market Overview by Product
Cancer Immunotherapy Product Market Overview by Global Region
Monoclonal Antibodies
Oncolytic Viral Therapies & Cancer Vaccines
Checkpoint Inhibitors & Immunomodulators
Global Cancer Immunotherapy Market Overview by Application
Cancer Immunotherapy Application Market Overview by Global Region
Lung Cancer
Breast Cancer
Colorectal Cancer
Skin Cancer
Prostate Cancer
Stomach Cancer
Head & Neck Cancer
Others
Global Cancer Immunotherapy Market Overview by End-User
Cancer Immunotherapy End-User Market Overview by Global Region
Hospitals & Clinics
Cancer Research Centers
Other End-Users
PART B: REGIONAL MARKET PERSPECTIVE
Global Cancer Immunotherapy Market Overview by Geographic Region
REGIONAL MARKET OVERVIEW
6. North America
North American Cancer Immunotherapy Market Overview by Geographic Region
North American Cancer Immunotherapy Market Overview by Product
North American Cancer Immunotherapy Market Overview by Application
North American Cancer Immunotherapy Market Overview by End-User
Country-wise Analysis of North American Cancer Immunotherapy Market
The United States
United States Cancer Immunotherapy Market Overview by Product
United States Cancer Immunotherapy Market Overview by Application
United States Cancer Immunotherapy Market Overview by End-User
Canada
Canadian Cancer Immunotherapy Market Overview by Product
Canadian Cancer Immunotherapy Market Overview by Application
Canadian Cancer Immunotherapy Market Overview by End-User
Mexico
Mexican Cancer Immunotherapy Market Overview by Product
Mexican Cancer Immunotherapy Market Overview by Application
Mexican Cancer Immunotherapy Market Overview by End-User
7. Europe
European Cancer Immunotherapy Market Overview by Geographic Region
European Cancer Immunotherapy Market Overview by Product
European Cancer Immunotherapy Market Overview by Application
European Cancer Immunotherapy Market Overview by End-User
Country-wise Analysis of European Cancer Immunotherapy Market
Germany
German Cancer Immunotherapy Market Overview by Product
German Cancer Immunotherapy Market Overview by Application
German Cancer Immunotherapy Market Overview by End-User
France
French Cancer Immunotherapy Market Overview by Product
French Cancer Immunotherapy Market Overview by Application
French Cancer Immunotherapy Market Overview by End-User
The United Kingdom
United Kingdom Cancer Immunotherapy Market Overview by Product
United Kingdom Cancer Immunotherapy Market Overview by Application
United Kingdom Cancer Immunotherapy Market Overview by End-User
Italy
Italian Cancer Immunotherapy Market Overview by Product
Italian Cancer Immunotherapy Market Overview by Application
Italian Cancer Immunotherapy Market Overview by End-User
Spain
Spanish Cancer Immunotherapy Market Overview by Product
Spanish Cancer Immunotherapy Market Overview by Application
Spanish Cancer Immunotherapy Market Overview by End-User
Rest of Europe
Rest of Europe Cancer Immunotherapy Market Overview by Product
Rest of Europe Cancer Immunotherapy Market Overview by Application
Rest of Europe Cancer Immunotherapy Market Overview by End-User
8. Asia-Pacific
Asia-Pacific Cancer Immunotherapy Market Overview by Geographic Region
Asia-Pacific Cancer Immunotherapy Market Overview by Product
Asia-Pacific Cancer Immunotherapy Market Overview by Application
Asia-Pacific Cancer Immunotherapy Market Overview by End-User
Country-wise Analysis of Asia-Pacific Cancer Immunotherapy Market
Japan
Japanese Cancer Immunotherapy Market Overview by Product
Japanese Cancer Immunotherapy Market Overview by Application
Japanese Cancer Immunotherapy Market Overview by End-User
China
Chinese Cancer Immunotherapy Market Overview by Product
Chinese Cancer Immunotherapy Market Overview by Application
Chinese Cancer Immunotherapy Market Overview by End-User
India
Indian Cancer Immunotherapy Market Overview by Product
Indian Cancer Immunotherapy Market Overview by Application
Indian Cancer Immunotherapy Market Overview by End-User
South Korea
South Korean Cancer Immunotherapy Market Overview by Product
South Korean Cancer Immunotherapy Market Overview by Application
South Korean Cancer Immunotherapy Market Overview by End-User
Rest of Asia-Pacific
Rest of Asia-Pacific Cancer Immunotherapy Market Overview by Product
Rest of Asia-Pacific Cancer Immunotherapy Market Overview by Application
Rest of Asia-Pacific Cancer Immunotherapy Market Overview by End-User
9. South America
South American Cancer Immunotherapy Market Overview by Geographic Region
South American Cancer Immunotherapy Market Overview by Product
South American Cancer Immunotherapy Market Overview by Application
South American Cancer Immunotherapy Market Overview by End-User
Country-wise Analysis of Asia-Pacific Cancer Immunotherapy Market
Brazil
Brazilian Cancer Immunotherapy Market Overview by Product
Brazilian Cancer Immunotherapy Market Overview by Application
Brazilian Cancer Immunotherapy Market Overview by End-User
Argentina
Argentine Cancer Immunotherapy Market Overview by Product
Argentine Cancer Immunotherapy Market Overview by Application
Argentine Cancer Immunotherapy Market Overview by End-User
Rest of South America
Rest of South American Cancer Immunotherapy Market Overview by Product
Rest of South American Cancer Immunotherapy Market Overview by Application
Rest of South American Cancer Immunotherapy Market Overview by End-User
10. Rest of World
Rest of World Cancer Immunotherapy Market Overview by Product
Rest of World Cancer Immunotherapy Market Overview by Application
Rest of World Cancer Immunotherapy Market Overview by End-User
PART C: GUIDE TO THE INDUSTRY
PART D: ANNEXURE
1. RESEARCH METHODOLOGY
2. FEEDBACK
